|
|
Article: BioNanomatrix Awarded Supplemental Funding to Accelerate Commercialization of Innovative Single-Molecule Analyzer.
- Article from:
- PR Newswire
- Article date:
- October 15, 2009
CopyrightCOPYRIGHT 2009 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
--New Grants of $833,490 Bring NHGRI Phase II Support for Commercial Development of the Company's NanoAnalyzer(R) Imaging and Analysis Platform to Over $2.8 Million-- --Support Planned Initiation of Beta Site Testing in Second Quarter of 2010--
PHILADELPHIA, Oct. 15 /PRNewswire/ -- BioNanomatrix, Inc., a developer of breakthrough single-molecule genomic analysis technology, today announced receipt of two new supplemental grants totaling $833,490 from the National Human Genome Research Institute (NHGRI) of the U.S. National Institutes of Health (NIH). The funding is intended to support further commercial development of BioNanomatrix's nanoscale whole genome ...